Loading
A phase 1 trial of CYNK-001 run by Celularity Incorporated, of unknown status on the registry.
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma is a phase 1 interventional study registered as NCT04309084 by Celularity Incorporated, with 29 participants planned, started 2020-05-12. Conditions recorded: Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorder, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Antineoplastic Agents, Analgesics, Non-Narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents and Physiological Effects of Drugs. Interventions recorded: CYNK-001.
Shares CYNK-001, Celularity, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CYNK-001, Celularity and the tag pipeline.
Shares CYNK-001, Celularity and the tag pipeline.
Shares Multiple myeloma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/